YC-1 can activate platelet soluble GCS (guanylate cylcase) indepedent of nitric oxide activation. It has the ability to inhibit aggregation of platelets and increase the platelets cAMP and cGMP content, as well as act as an antithrombotic compound. Data shows that the highest activation of GCS is observed in the presence of YC-1. The compound can suppress HIF-1 α activity in neonatal rat ventricular myocytes. Research shows that GCS activators (YC-1) might have the ability to activate the sGC/cGMP/PKG pathway and influence the activation of Ras/Raf-1/p44/42 MAPK. YC-1 is an activator of GCS (guanylate cylcase). YC-1 is an inhibitor of HIF-1 α.
1. Ko, F.N., et al. 1994. Blood. 84: 4226-4233. PMID: 7527671 2. Wu, C.C., et al. 1995. Br. J. Pharmacol. 116: 1973-1978. PMID: 8640334 3. Stone, J.R. and Marletta, M.A. 1998. Chem. Biol. 5: 255-261. PMID: 9646941 4. Chang, M.S., et al. 2009. Pharmacol. Res. 60: 247-253. PMID: 19717011 5. Zhou, Y.F., et al. 2010. Cardiovasc J Afr. 21: 37-41. PMID: 20224844
Soluble in DMSO (12 mg/ml), methanol (5 mg/ml), ethanol (50 mM), DMF (~20 mg/ml), 5:2 DMSO:PBS(pH 7.2) (~10 ug/ml), and dichloromethane. Insoluble in water.
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
Wang X; et alWang X; et al. (PubMed ID: 26350953) utilized YC-1, HIF1a inhibitor, to determine the effect of HIF1a in hypoxia induced down-regulation of BCL-2 and up-regulation of miR-20. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn